Latest news with #AIMVaccine
Yahoo
19-05-2025
- Business
- Yahoo
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine ( a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international benchmark products. AIM Vaccine's mRNA platform capabilities are once again in the spotlight. Fosun International Securities recently noted in a research report that AIM's mRNA shingles vaccine could challenge the existing market landscape with its potential for superior efficacy and safety. Immunogenicity Indicators Significantly Outperform International Benchmarks According to the announcement, preclinical trial results from third-party testing institutions demonstrate that AIM's mRNA shingles vaccine shows significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescent antibody (FAMA) titers compared to internationally marketed recombinant subunit control vaccines. Furthermore, there are currently no mRNA-based shingles vaccines approved for marketing globally. According to recently published industry references, the vaccination rate for shingles vaccines among PRC's target population is less than 1%, indicating enormous growth potential. Fosun International Securities' research report analysis mentions that as PRC's first company to establish a complete mRNA vaccine R&D system, its technological approach successfully avoids existing shingles vaccine patent barriers, creating favorable conditions for entering the global market projected to reach US$23.9 billion annually. mRNA Platform Capabilities Continue to Lead the Industry The competition in mRNA technology platforms between domestic and international companies has reached intensity comparable to an arms race, with infectious disease and cancer vaccines being the key battlegrounds. AIM Vaccine leads the industry through breakthrough progress in infectious disease vaccines. Fosun International Securities' research report released in late March pointed out that AIM Vaccine holds a leading position in PRC's mRNA vaccine field, having obtained 11 clinical approvals across 6 countries, including 2 FDA approvals in the U.S. Its platform technology has been validated by favorable safety and efficacy clinical data from over 10,000 subjects. This latest approval for its mRNA shingles vaccine in PRC further highlights the company's leading position in next-generation vaccine technology and rapid commercialization potential. Some industry observers believe that if PRC companies can continue to overcome core patents, expand indications, and deepen international cooperation, mRNA technology may become a hallmark area for PRC's biopharmaceutical industry to achieve technological leapfrogging. In this cutting-edge field, AIM Vaccine has not only secured clinical approvals in both PRC and the U.S. for its mRNA shingles vaccine and mRNA RSV vaccine, but also has its next-generation mRNA rabies vaccine and mRNA influenza vaccine in pre-IND review and preclinical studies respectively, demonstrating the platform's strong extensibility and laying a solid foundation for sustained development and market leadership. As analyzed by multiple investment institutions, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it a highly attractive investment choice. They remain optimistic about the company's development prospects driven by industry recovery and new products, and believe its valuation has significant upside potential. View original content: SOURCE AIM Vaccine
Yahoo
19-05-2025
- Business
- Yahoo
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine ( a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international benchmark products. AIM Vaccine's mRNA platform capabilities are once again in the spotlight. Fosun International Securities recently noted in a research report that AIM's mRNA shingles vaccine could challenge the existing market landscape with its potential for superior efficacy and safety. Immunogenicity Indicators Significantly Outperform International Benchmarks According to the announcement, preclinical trial results from third-party testing institutions demonstrate that AIM's mRNA shingles vaccine shows significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescent antibody (FAMA) titers compared to internationally marketed recombinant subunit control vaccines. Furthermore, there are currently no mRNA-based shingles vaccines approved for marketing globally. According to recently published industry references, the vaccination rate for shingles vaccines among PRC's target population is less than 1%, indicating enormous growth potential. Fosun International Securities' research report analysis mentions that as PRC's first company to establish a complete mRNA vaccine R&D system, its technological approach successfully avoids existing shingles vaccine patent barriers, creating favorable conditions for entering the global market projected to reach US$23.9 billion annually. mRNA Platform Capabilities Continue to Lead the Industry The competition in mRNA technology platforms between domestic and international companies has reached intensity comparable to an arms race, with infectious disease and cancer vaccines being the key battlegrounds. AIM Vaccine leads the industry through breakthrough progress in infectious disease vaccines. Fosun International Securities' research report released in late March pointed out that AIM Vaccine holds a leading position in PRC's mRNA vaccine field, having obtained 11 clinical approvals across 6 countries, including 2 FDA approvals in the U.S. Its platform technology has been validated by favorable safety and efficacy clinical data from over 10,000 subjects. This latest approval for its mRNA shingles vaccine in PRC further highlights the company's leading position in next-generation vaccine technology and rapid commercialization potential. Some industry observers believe that if PRC companies can continue to overcome core patents, expand indications, and deepen international cooperation, mRNA technology may become a hallmark area for PRC's biopharmaceutical industry to achieve technological leapfrogging. In this cutting-edge field, AIM Vaccine has not only secured clinical approvals in both PRC and the U.S. for its mRNA shingles vaccine and mRNA RSV vaccine, but also has its next-generation mRNA rabies vaccine and mRNA influenza vaccine in pre-IND review and preclinical studies respectively, demonstrating the platform's strong extensibility and laying a solid foundation for sustained development and market leadership. As analyzed by multiple investment institutions, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it a highly attractive investment choice. They remain optimistic about the company's development prospects driven by industry recovery and new products, and believe its valuation has significant upside potential. View original content: SOURCE AIM Vaccine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-05-2025
- Business
- Yahoo
Asian Penny Stocks To Watch In May 2025
Amidst easing trade tensions and positive earnings reports, Asian markets are navigating a complex economic landscape marked by cautious optimism. In such a setting, penny stocks—often representing smaller or newer companies—offer intriguing growth opportunities at lower price points. While the term "penny stock" may seem outdated, these investments can still hold significant potential when backed by strong financial health and solid fundamentals. Name Share Price Market Cap Financial Health Rating Advice IT Infinite (SET:ADVICE) THB4.84 THB3B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.41 SGD166.17M ★★★★★☆ YKGI (Catalist:YK9) SGD0.10 SGD42.5M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.189 SGD37.65M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.25 SGD8.86B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.93 HK$3.34B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.06 HK$46.48B ★★★★★★ Lever Style (SEHK:1346) HK$1.06 HK$668.81M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.15 HK$1.92B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.95 HK$1.62B ★★★★★★ Click here to see the full list of 1,170 stocks from our Asian Penny Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: AIM Vaccine Co., Ltd. focuses on the research, development, manufacturing, and commercialization of vaccines for human use in China and has a market cap of approximately HK$4.29 billion. Operations: The company's revenue primarily comes from the sale of vaccines and research and development services, totaling CN¥1.29 billion. Market Cap: HK$4.29B AIM Vaccine Co., Ltd. is positioned as a promising entity in the Asian penny stock landscape, driven by its focus on vaccine innovation and development. Despite being unprofitable with increasing losses over five years, AIM has shown resilience through its strategic advancements in mRNA technology. Recent approvals for clinical trials of its mRNA shingles and RSV vaccines by the U.S. FDA highlight its potential for international market penetration. The company's serum-free rabies vaccine marks a significant technological breakthrough, potentially enhancing safety and reducing adverse reactions compared to traditional vaccines, which may bolster future revenue growth prospects amidst high volatility in share price. Dive into the specifics of AIM Vaccine here with our thorough balance sheet health report. Understand AIM Vaccine's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Youzan Technology Limited is an investment holding company offering online and offline e-commerce solutions in China, Japan, and Canada with a market cap of HK$3.13 billion. Operations: The company's revenue is primarily derived from Merchant Services, generating CN¥1.18 billion, and Third Party Payment Services, contributing CN¥313.19 million. Market Cap: HK$3.13B Youzan Technology Limited, an investment holding company in the e-commerce sector, has faced financial challenges with a net loss of CN¥176.62 million for 2024 despite generating sales of CN¥1.44 billion. The company's debt to equity ratio has increased significantly over five years, yet it maintains a robust cash position that exceeds its total debt and covers long-term liabilities. Recent strategic moves include a share buyback program and board changes aimed at strengthening governance. While unprofitable, Youzan's positive free cash flow provides a runway exceeding three years, offering some stability amidst market volatility. Take a closer look at Youzan Technology's potential here in our financial health report. Assess Youzan Technology's future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Bona Film Group Co., Ltd. is involved in film production and distribution in China, with a market cap of CN¥6.01 billion. Operations: Bona Film Group Co., Ltd. does not report specific revenue segments. Market Cap: CN¥6.01B Bona Film Group Co., Ltd. has reported a significant net loss of CN¥955.17 million for Q1 2025, despite increased revenue of CN¥525.42 million compared to the previous year. The company remains unprofitable with a negative return on equity and has experienced growing losses over the past five years at a rate of 60.7% annually. However, it maintains satisfactory debt levels with a net debt to equity ratio of 34.6% and strong short-term asset coverage for liabilities, suggesting financial resilience in the short term despite ongoing challenges in profitability and board inexperience. Click to explore a detailed breakdown of our findings in Bona Film Group's financial health report. Review our growth performance report to gain insights into Bona Film Group's future. Jump into our full catalog of 1,170 Asian Penny Stocks here. Contemplating Other Strategies? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:6660 SEHK:8083 and SZSE:001330. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
27-02-2025
- Business
- Yahoo
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd.(a joint stock company incorporated in the People's Republic of China with limited liability)(Stock Code: HONG KONG, Feb. 27, 2025 /PRNewswire/ -- The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine ( announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration (FDA). The vaccine shows significantly higher humoral and cellular immunity compared to international marketed products. This product is expected to become a new growth driver for AIM Vaccine. Analysts believe that the recent popularity of AI healthcare concepts in the Hong Kong stock market, benefiting from the recovery in market demand, performance growth, and rapid international expansion, is drawing more attention to the booming biopharmaceutical industry. In line with the overall positive industry trend, AIM Vaccine has recently published several announcements, not only fully integrating DeepSeek's large model to drive deep penetration of AI technology across the research, production, sales, and management sectors but also initiating a strategic upgrade to become an "AI + Smart Vaccine Enterprise." Its ongoing mRNA RSV vaccine and mRNA shingles vaccine have both made significant progress, particularly the mRNA RSV vaccine obtaining U.S. clinical approval in a short time, demonstrating its innovation strength and instilling firm confidence in its performance growth and international expansion. Fosun International Securities' initial coverage report1 on AIM Vaccine notes that the company, leveraging its differentiated technological advantages and comprehensive product layout, not only displays significant leading potential in the domestic market but also has broad prospects for expansion in the international market, positioning itself to occupy an important place in the global vaccine market. At this point in time, looking at the entire Hong Kong pharmaceutical sector, data tracked by Zheshang International shows that as of the week of February 23, the overall PE valuation level for the Hong Kong healthcare industry remains below the average since 2018, and there is still a significant gap compared to the peak levels. Ping An Securities points out2, "Various policies supporting innovative drugs are being rolled out, and we believe the innovative drug sector has clear positive signals from a policy perspective." Sinolink Securities anticipates that recent A-share and Hong Kong-listed pharmaceutical companies are about to enter their annual report window, expecting a sector-wide performance reversal post-reports, and the subsequent improvement in operational conditions and changes in performance rhythm are worth continuous tracking. Focusing on AIM Vaccine as a leader in the vaccine industry, the Fosun International Securities research report suggests that AIM Vaccine's valuation is lower than that of major Chinese competitors and global vaccine giants, indicating an overreaction by the market to its short-term losses and still low expectations for growth or profitability. The report predicts that from 2024 to 2027, AIM Vaccine's revenue compound annual growth rate (CAGR) will reach 47%, with a projected breakeven in 2025 and net profit expected to exceed RMB 1.52 billion by 2027. The approval of AIM Vaccine's mRNA RSV vaccine for clinical trials in the U.S. is seen by analysts as further validation of the company's "Innovation + Expansion" capabilities, potentially providing substantial support for the company's performance growth and valuation recovery. Note 1: Note 2: View original content: SOURCE AIM Vaccine Sign in to access your portfolio
Zawya
06-02-2025
- Business
- Zawya
AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.
Multiple Institutions Give AIM a "Buy" Rating HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. ( a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug Administration (FDA). The vaccine has demonstrated significantly higher humoral and cellular immunity compared to internationally marketed products. If the product progresses smoothly, it will accelerate AIM Vaccine's international expansion and contribute to substantial performance growth. In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing antibody potency, and specific T-cell immunity compared to internationally marketed mRNA RSV control vaccines. This announcement highlights AIM Vaccine's innovative capabilities and underscores the acceleration of its internationalization efforts, which have been recognized by multiple institutions. Recently, FOSUN INTERNATIONAL SECURITIES initiated coverage of AIM Vaccine, assigning a "Buy" rating with a 12-month target price of HKD 11.0. The report cited the company's strong product pipeline, technological leadership, and potential for international growth as key factors. Similarly, SDICSI released a research report predicting that AIM Vaccine will launch 1-2 products annually over the next three years. If the products in development gain approval and progress smoothly in international markets, they are expected to drive new performance growth and expand market potential. SDICSI also assigned a "Buy" rating with a target price of HKD 9.5. FOSUN INTERNATIONAL SECURITIES's analysis indicates that the Chinese vaccine market is evolving in line with global trends, where high-value products and leading companies dominate. With its differentiated advantages, AIM Vaccine is poised to secure a leading position in the domestic market while achieving scalable expansion internationally. Additionally, the company's comprehensive and iterative product portfolio is expected to enhance its market share, pricing power, and profitability, further supporting long-term growth. The report also emphasized that AIM Vaccine, with its diversified product portfolio, technological strengths, and global expansion strategy, presents an attractive investment opportunity for investors. With a series of high-value products set to launch and profitability expected to rebound from 2025 onwards, the company is positioned for strong growth and potential valuation reassessment. Globally, there are currently no approved antiviral drugs for RSV available for clinical use. Vaccination for active immune prophylaxis remains the most effective means to prevent severe RSV infections. No RSV vaccines have been approved for marketing in PRC. In 2023, global sales of RSV vaccines reached USD 2.46 billion, and according to industry consultants, the market size is expected to grow to approximately USD 16.7 billion by 2030. The mRNA vaccine field is still wide open with plenty of opportunities, as there are few competitors globally. AIM Vaccine is one of the earliest companies in PRC to develop mRNA vaccine products and is among the first domestic vaccine enterprises to obtain independent patents for mRNA technology. The company has established a mature mRNA vaccine R&D system and has developed multiple mRNA candidate vaccines, including vaccines for shingles, rabies, and influenza, in addition to the mRNA RSV vaccine. Hashtag: #AIMVaccine The issuer is solely responsible for the content of this announcement. AIM Vaccine
